Fresenius commits to more PROSORBA columns:
This article was originally published in Clinica
Cypress Bioscience has secured further orders from Fresenius Medical Care North America for its PROSORBA column in an expansion to Fresenius' pilot programme of the FDA-approved device. The PROSORBA reduces symptoms in moderate to severe rheumatoid arthritis in hard-to-treat patients. Fresenius has bought a further 1,000 units and will buy a similar number in the third and fourth quarters to support the pilot doctor's office study and hospital use.
You may also be interested in...
Can shaving ever be “friction free”? Not according to Procter & Gamble, which challenged in a complaint to the UK Advertising Standards Authority a claim made by a British cosmetics firm FFS that it provided a “friction free” shaving experience for women via its subscription razor service.
Work has started on UK-only regulations for the medtech and medicines sectors, to ensure that the regulatory framework not only functions but can also react swiftly to needs after the UK leaves the EU. This article is part two of two.